Trials / Conditions / Advanced or Metastatic Non-small Cell Lung Cancer

Advanced or Metastatic Non-small Cell Lung Cancer

11 registered clinical trials studyying Advanced or Metastatic Non-small Cell Lung Cancer — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782	AstraZeneca	Phase 1 / Phase 2
Recruiting	Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemo NCT07170995	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3
Recruiting	A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors NCT06581419	SUNHO（China）BioPharmaceutical CO., Ltd.	Phase 1 / Phase 2
Recruiting	A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-sm NCT06512051	Shanghai Hengrui Pharmaceutical Co., Ltd.	Phase 1 / Phase 2
Recruiting	Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutati NCT06674343	Peking Union Medical College Hospital	Phase 3
Recruiting	Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667	Gilead Sciences	Phase 2
Terminated	Phase I Study of the BBP-398 in Patients With Advance Solid Tumors NCT05621525	LianBio LLC	Phase 1
Active Not Recruiting	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer NCT05450692	AstraZeneca	Phase 3
Active Not Recruiting	A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With NCT05388669	Janssen Research & Development, LLC	Phase 3
Completed	A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 NCT02855125	Taiho Oncology, Inc.	Phase 2
Completed	Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small NCT00716534	AbbVie (prior sponsor, Abbott)	Phase 2